Drug Profile
Research programme: cancer therapeutics - EpimAb/Kymab
Latest Information Update: 14 Apr 2021
Price :
$50
*
At a glance
- Originator Epimab Biotherapeutics; Kymab
- Developer EpimAb Biotherapeutics; Kymab
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Apr 2021 Kymab has been acquired by Sanofi
- 28 Nov 2020 No recent reports of development identified for research development in Cancer in China
- 28 Nov 2020 No recent reports of development identified for research development in Cancer in United Kingdom